May 9 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2019 RESULTS AND REAFFIRMS GUIDANCE.Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.30.Q1 GAAP EARNINGS PER SHARE $0.04.Q1 REVENUE $52.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $50.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.05 -- REFINITIV IBES DATA.REAFFIRMED ITS 2019 FINANCIAL GUIDANCE.
Full Article
Dec 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS - ON DEC 27,CO, UNITS ENTERED INTO AMENDED & RESTATED 5-YEAR SENIOR SECURED CREDIT AMENDING CREDIT FACILITY DATED DEC 29, 2017.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT ADDS DELAYED DRAW TERM LOAN FACILITY IN AN AMOUNT UP TO $118.0 MILLION.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT INCREASES BORROWING CAPACITY UNDER REVOLVING LINE OF CREDIT BY $25.0 MILLION TO $75.0 MILLION - SEC FILING.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT ALSO EXTENDS MATURITY, INCLUDING OUTSTANDING $72.2 MILLION INITIAL TERM LOAN, TO DEC 27, 2023.ANI PHARMACEUTICALS SAYS TOTAL SIZE OF AMENDED CREDIT AGREEMENT IS $265.2 MILLION FOLLOWING AMENDMENT AND RESTATEMENT - SEC FILING.
Full Article
Nov 6 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS THIRD QUARTER AND YEAR-TO-DATE 2018 RESULTS AND REAFFIRMS GUIDANCE.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.29.Q3 GAAP EARNINGS PER SHARE $0.42.Q3 REVENUE $50.7 MILLION VERSUS I/B/E/S VIEW $51 MILLION.Q3 EARNINGS PER SHARE VIEW $1.17 -- THOMSON REUTERS I/B/E/S.SAYS REAFFIRMED ITS 2018 FINANCIAL GUIDANCE.
Full Article
April 4 (Reuters) - ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single ::ANI ACQUIRES 23 ANDAS FROM IDT AUSTRALIA, LTD..DIGIT ROYALTY FOR ONE PRODUCT.
Full Article
Feb 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.08.Q4 REVENUE ROSE 24 PERCENT TO $47.3 MILLION.QTRLY GAAP NET LOSS INCLUDES IMPACT OF $13.4 MILLION CHARGE DUE TO TAX CUTS AND JOBS ACT.QTRLY DILUTED GAAP LOSS PER SHARE OF $0.83.SEES 2018 NET REVENUES OF $212 MILLION TO $228 MILLION.SEES 2018 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.43 TO $6.08.PLANS TO INVEST APPROXIMATELY $7 MILLION IN CAPITAL PROJECTS DURING 2018.
Full Article
Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.
Full Article
Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees for full year 2017 net revenues $181 million to $183 million.ANI Pharmaceuticals Inc sees for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan.
Full Article
Sept 1 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals Inc announces approval and launch of Oxycodone Hydrochloride oral solution, 100 mg/5ml.ANI Pharmaceuticals Inc - ANI expects to begin shipping oxycodone hydrochloride oral solution, 100 mg/5ml to its customers immediately.ANI Pharmaceuticals Inc - received approval from U.S. FDA of its ANDA for Oxycodone Hydrochloride oral solution USP, 100 mg/5 ml.
Full Article
Aug 3 (Reuters) - Ani Pharmaceuticals Inc :Ani Pharmaceuticals reports record second quarter and year-to-date 2017 results and reaffirms guidance.Q2 adjusted non-GAAP earnings per share $0.98.Q2 GAAP earnings per share $0.23.Q2 revenue $44.8 million versus I/B/E/S view $43.2 million.Q2 earnings per share view $0.86 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $181 million to $190 million.Ani Pharmaceuticals Inc says reaffirms guidance for full year 2017.FY 2017 revenue view $182.6 million -- Thomson Reuters I/B/E/S.
Full Article
Earnings vs. 
Estimates